Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
- Status
- COMPLETED
- Phase
- PHASE2
Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography
- Status
- UNKNOWN
- Phase
- PHASE4
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
- Status
- TERMINATED
- Phase
- PHASE1
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
- Status
- TERMINATED
- Phase
- PHASE1
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
- Status
- COMPLETED
- Phase
- PHASE2
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
- Status
- COMPLETED
- Phase
- PHASE4
Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
- Status
- COMPLETED
- Phase
- PHASE3
Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome
- Status
- COMPLETED
- Phase
- N/A
DPP4 Inhibition & Beta Cell Function
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2